Rise Nano Optics Ltd. · CSE:EYE
Rise Nano Optics — Investor Presentation (August 2026)
24 slides from Rise Nano Optics's investor presentation, August 2026
Slide 1: Setting a New Standard in Eyewear
Setting a New Standard in Eyewear. FDA-REGISTERED CLASS 1 DEVICE Investor Presentation – August 2026
Slide 2: Investment Highlights
Investment Highlights TM Rise is redefining the optical lens market with SpectraGuard , a patented nano particle optical lens treatment that sets a new standard of eye protection. We scale by selling to existing lens manufacturers, 3rd party optical labs, eyewear brands, DTC eyewear businesses, eye
Slide 3: A Patented Scientific Breakthrough
A PATENTED SCIENTIFIC BREAKTHROUGH
Slide 4: Game Changing Nanotechnology & Performance
Game Changing Nanotechnology & Performance UV + 400–600nm PATENTED NANO TECHNOLOGY MORE PROTECTION FROM THE SUN REDUCE GLARE, IMPROVED CONTRAST Light Source SpectraGuard Standard Lens EYE Rise’s patented lens treatment permanently integrates nano- SpectraGuard is the only lens treatment capable of f
Slide 5: Positive Impact Shown In Peer-Reviewed Study
Positive Impact Shown In Peer-Reviewed Study Conducted at The Technion – Israel Institute of Technology using diabetic rats. In a healthy eye, Müller cells stabilize and nourish the retina, playing a critical role in vision quality. GFAP, a marker of cellular stress, appearing in Müller cells signal
Slide 6: Strong Patent Protection
Strong Patent Protection Patent Status Country & Date Medical Patent USA & India Method and a system for protection of retina from a light (Licensed from the Technion Institute of Technology of Israel) No. 8833937 (USA) 16-Sep-2014 induced damage GRANTED No. 316658 (INDIA) 23-Jul-2019 USA Products u
Slide 7: One Technology, Multiple Markets
ONE TECHNOLOGY, MULTIPLE MARKETS
Slide 8: Performance Sunglasses
Performance Sunglasses Global Sunglasses Market Valued At USD $43.03 Billion In 2025 Market Projected To Reach USD $111.61 Billion By 2033 North America Accounted For 31% Of 2025 Global Revenue Premium Offerings Above USD $150 Accounted For 62% Of Sales SpectraGuard provides superior sun protection
Slide 9: Blue Light Glasses
Blue Light Glasses Blue Light Glasses Market Valued At USD $3.0 Billion In 2025 Market Projected To Reach USD $6.4 Billion By 2035 Key Growth Regions include: North America, Asia-Pacific, Europe 58% of Blue Light Glasses Are Prescription SpectraGuard Photochromic combines broader protection from ind
Slide 10: Light Sensitivity & Photophobia
Light Sensitivity & Photophobia Migraine Sufferers – 1 Billion People Worldwide Light Sensitivity (Photophobia) affects 80% of people with Migraines Dry Eye Sufferers – 344 Million Worldwide Light Sensitivity (Photophobia) affects 75% of people with DED SpectraGuard can help those that suffer from l
Slide 11: Degenerative Eye Disease Management
Degenerative Eye Disease Management Diabetic Retinopathy – 100 Million People Worldwide Macular Degeneration – 200 Million Worldwide Cataracts – 100 Million Worldwide SpectraGuard can replace and outperform dozens of various lenses used to support patients with degenerative eye disease.
Slide 12: A Low Capex GTM
A LOW CAPEX GTM
Slide 13: Commercial Revenue Streams
Commercial Revenue Streams Our Revenue Streams Don't Just Generate Revenue — They Generate Demand. Partner Lab & DTC Eyewear Licensing Rise-Owned Optical Labs & Lens Manufacturer Licensing Eye Care Professional Sales SpectraGuard Licensed To Large Volume DTC SpectraGuard Licensed To Leading Eyewear
Slide 14: A Capital-Efficient GTM Fuelled by B2B Marketing
A Capital-Efficient GTM Fuelled by B2B Marketing Strong B2B marketing drives lab adoption and ECP demand — with compelling margins and superior protection as the foundation, every dollar of spend works harder. Our partnership-first approach allows us to build significant production and distribution
Slide 15: Key Go To Market (GTM) Markets
Key Go To Market (GTM) Markets North High and rising prevalence of chronic retinal disease. EU Large elderly population drives MD and cataract demand. America Strong clinical acceptance of specialty and therapeutic lenses. Japan High prevalence of vision correction and optical device usage. Defined
Slide 16: Primary Near-Term US & EU Sales Channels
Primary Near-Term US & EU Sales Channels INDEPENDENT ECPS OPTICAL CHAINS
Slide 17: Primary Short to Mid-Term US & EU Sales Channels
Primary Short to Mid-Term US & EU Sales Channels ALLIANCES/ MASS MERCHANT / WHOLESALERS CLINICS / HOSPITALS GENERAL RETAIL BUYING GROUPS WAREHOUSE Retina and Vitreous Clinic Braden Diabetes Center
Slide 18: ECP Awareness and Demand Generation
ECP Awareness and Demand Generation Trade Media: Integrated Print and Digital Media Campaign Rise will leverage print, web, email, digital newsletter, and video advertising opportunities as well as outreach to each publication’s editorial staff to promote SpectraGuard.
Slide 19: ECP Awareness and Demand Generation
ECP Awareness and Demand Generation ECP Sales Enablement In-Store Signage Tri-Fold Brochure Web, Social, & Email Assets Whitepapers & Technical Documents ECP & Consumer Versions
Slide 20: Winning Leadership
WINNING LEADERSHIP
Slide 21: Experienced Leadership
Experienced Leadership Backed by a team of industry leaders and experts in the medical field with proven track record of delivery and success
Slide 22: Cap Table
CAP TABLE
Slide 23: Pro Forma Cap Table
Pro Forma Cap Table • Go Public Q1 2026 Rise Nano Optics Ltd • CSE under “EYE” • RTO Financing Round:~C$4.0M Common Shares 40,374,904 (Complete) Warrants 11,255,646 Contingent Rights 9,331,785 Options 456,308 RSUs 4,053,825 Fully Diluted 65,472,468 Escrow Terms • ~85% of shares are locked up and can
Slide 24: Thank You For Your Consideration
Thank You For Your Consideration Investor Contacts Julia Becker Erik Ritchie Investor Relations Chief Commercialization Officer E: julia@strikecomm.com E: erik.ritchie@risenanooptics.com Investor Presentation – August 2026
Rise Nano Optics — Investor Presentation (August 2026) on 6ix